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Abstract
Craig Thomas Wiltsey
SELF-ASSEMBLING BIOMIMETIC HYDROGELS WITH BIOADHESIVE
PROPERTIES FOR TISSUE ENGINEERING APPLICATIONS
2011/12
Jennifer Vernengo, Ph.D.
Master of Science in Engineering
Tissue engineering is a multidisciplinary field that aims to repair or regenerate
lost or damaged tissues and organs in the body. For the repair of certain load-bearing
parts of the body, success of a tissue regeneration strategy can be dependent on scaffold
adhesion or integration with the surrounding host tissue to prevent dislocation. One such
area is the regeneration of the intervertebral disc (IVD). The objective of this work is to
generate a bioadhesive polymer that, in addition to bonding with tissue, can support
encapsulated cell survival post-adhesion. Thermosensitive poly(N-isopropylacrylamide)
(PNIPAAm) was grafted with chondroitin sulfate (CS) (PNIPAAm-g-CS) and blended
with aldehyde-modified CS to achieve covalent adhesion upon contact with
tissue. Extracellular matrix (ECM) loaded lipid vesicles (liposomes) were incorporated
into the copolymer for enhanced cellular biocompatibility. The bioadhesive strength was
evaluated in contact with porcine ear cartilage. Additionally, the cytotoxicity of the
samples was investigated using a PicoGreen quantitative assay.
Incorporating CS aldehyde into the polymer increased the adhesive strength
compared to PNIPAAm-g-CS polymer alone (p<0.05), while incorporation of ECM
loaded liposomes significantly decreased adhesive strength (p<0.05). As lipid
concentration increased there were decreasing trends in adhesive strength. Preliminary
biocompatibility studies indicate that incorporation of ECM loaded liposomes reduced
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cytotoxicity over the copolymer blended with CS aldehyde and no liposomes. Future
work will investigate other means of ECM encapsulation to optimize both adhesive
strength and biocompatibility.
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Chapter 1
Introduction
Lower back pain is one of the most common medical problems world wide and
affects nearly 80% of American adults, costing nearly $90 billion annually [1] [2] [3] [4].
The main cause of lower back pain is the degeneration of the intervertebral disc (IVD),
resulting from the fall in viable cell population in the nucleus of the IVD and the
subsequent inability of the nucleus pulposus (NP) to bear compressive loads [5] [6] [7].
Unfortunately, current treatments for IVD degeneration and lower back pain range from
conservative treatments such as medications to more invasive techniques including
replacement of the IVD with an artificial disc or fusing the vertebrae [8]. There is a need
for a minimally invasive, tissue engineering strategy for repairing and regenerating
damaged intervertebral disc tissue.
Tissue engineering is a field that aims to regenerate damaged tissues by
incorporating cells into a mechanically stable scaffold [9]. Ideally, a tissue engineering
scaffold for repair and replacement of the IVD would overcome the highly invasive
nature of current treatments. While a number of tissue-engineered scaffolds have been
developed for the IVD, few exhibit the ideal mechanical characteristics to replace native
tissue. Additionally, there has been a reported problem of expulsion of implants in the
central NP migrating through the damaged annulus fibrosus (AF), making the need for an
adhesive scaffold paramount [10] [11].
As with tissue-engineered scaffolds, a number of tissue adhesive components have
been investigated. These range from the weakly adhesive but biocompatible fibrin
adhesive to strong but poorly biocompatible cyanoacrylate adhesives. In addition, a
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number of groups have developed bioadhesive components that show promise for tissue
adhesion. These adhesives are comprised chemically modified polysaccharide
components, functionalized with aldehyde groups and able to react with the tissue surface
via a Schiff’s base reaction [12] [13] [14] [15] [16] . Of particular interest are adhesive
components made of chondroitin sulfate, a native component of the IVD tissue.
Chondroitin sulfate has been modified by a number of researchers to form a novel
bioadhesive, however, to our knowledge, has not been incorporated into a tissue
engineering scaffold for the repair and regeneration of the IVD [15] [16].
This goal of this work is to develop an adhesive, in situ forming hydrogel, capable
of supporting encapsulated cells for the tissue engineering of the IVD. To this end, there
are three aims of the current work:
Aim 1: Synthesize an adhesive copolymer consisting of poly (N-isopropylacrylamide)
graft chondroitin sulfate blended with aldehyde modified chondroitin sulfate and
characterize the material properties
Aim 2: Prepare lipid vesicles hydrated with ECM derivatives, verify ECM derivative
release, and combine lipid vesicles with the scaffold prepared in Aim 1 and characterize
the adhesive properties of the system
Aim 3: Demonstrate the ability of the tissue engineering scaffold to support encapsulated
cell survival
In this work, a copolymer scaffold comprised of poly (N-isopropylacrylamide)
(PNIPAAm) graft chondroitin sulfate (CS) (PNIPAAm-g-CS) was investigated. The
scaffold is comprised mostly of PNIPAAm, allowing it to form in situ due to the presense
of the lower critical solution temperature (LCST) of PNIPAAm around 29.6°C [17].
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Additionally, CS, a native component of the IVD disc tissues allows the scaffold to
imbibe water, nutrients, maintain anti-inflammatory characteristics and be susceptible to
enzymatic degradation [18] [19]. To provide adhesive properties, aldehyde modified CS
(CS aldehyde) was physically blended into the copolymer. The adhesive properties of the
adhesive scaffold were investigated as the number of aldehyde groups and weight
percentage of CS aldehyde were varied within the system. The overall goal was to
develop a system with the maximum adhesive properties.
While CS aldehyde has been investigated as a tissue adhesive, aldehyde groups
have been shown to be cytotoxic to encapsulated cells [20] [21]. To combat this effect,
lipid vesicles (liposomes) were incorporated into the adhesive scaffold, capable of
releasing encapsulated extracellular matrix (ECM) derivatives, gelatin, at body
temperature. Gelatin is theorized to be capable of reacting with, or “capping” excess
aldehyde groups via the Schiff’s base reaction, preventing excess aldehyde groups from
being cytotoxic to encapsulated cells. The temperature controlled release is used to
ensure that gelatin “capping” does not interfere with the adhesive properties of the
system. The release of gelatin from the lipid vesicles and the mechanical properties of the
system when liposome concentration was varied were investigated. Finally, the viability
of cells seeded within the adhesive copolymer scaffold was tested to determine
biocompatibility. Ultimately, this copolymer scaffold has the potential to replace
antiquated techniques as a minimally invasive, alternative to highly invasive surgical
intervention for the treatment of lower back pain and IVD degeneration.
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Chapter 2
Background
2.1 – Spinal Anatomy
The spine can be subdivided into five specific regions, each having different
properties and performing slightly different functions. The cervical (neck) region is
comprised of 7 vertebrae, each having the smallest vertebral body but with relatively
thick IVDs. Traveling down the spine are 12 thoracic vertebrae, each with a slightly
larger vertebral body, but with relatively thinner IVDs. In the lower back are the 5 lumbar
vertebrae, which are comprised of the largest vertebral bodies and the largest IVDs. The
lumbar region is the main load-bearing region of the spine, and therefore is the strongest
portion of the spine. Beyond the lumbar are two fused sections with no IVDs, namely the
sacrum and the coccyx, with 5 and 4 fused vertebrae respectively [22]. Figure 1 shows
the different sections of the spine from both the back and side of the body.
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Figure 1: A view of the spine from the back and side, showing the five sections of the
spinal column [22]

The spine is comprised of several subcomponents, each performing a specific
function. The vertebrae, comprised of bone, provide structure and support. On the
anterior side of the vertebrae, facing the inside of the body is the thickest portion of the
vertebrae, the vertebral body. The vertebral body is the primary load bearing structure of
the vertebrae and therefore must be the thickest part of the vertebrae. Each vertebra also
features a small hole, the vertebral foramen, which allows the passage of nervous tissue,
blood vessels and additional connective tissues. Additionally, between each vertebra is a
collagen and fibrin rich region known as the intervertebral disc (IVD) [22]. Figure 2
shows the placement of the IVD between two vertebrae.
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Figure 2: A view of the intervertebral disc showing the body, nucleus pulposus,
annulus fibrosus and intervertebral foramen [22]

The IVDs of each region are all slightly different, however their overall
composition and structure are consistent in each of the three upper regions of the spine.
The IVD has two specific regions, the inner nucleus pulposus (NP) and the outer annulus
fibrosus (AF) [22]. The NP can be described as the gel-like region of the IVD located at
the center of the disc. The NP is highly hydrated matrix of aggrecan and proteoglycans
with embedded collagen and fibrin fibers. The hydrated nature of the NP allows it to
maintain pressure and bear compressive forces. Surrounding the NP is the AF, made of
collagen fibers arranged in concentric rings or lamellae [23]. The AF itself can consist of
approximately 15-25 rings surrounding the NP [24]. The main purpose of each IVD is to
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help absorb forces between each vertebrae and to allow the vertebra to move with respect
to one another [22].
2.2 – The Intervertebral Disc (IVD)
The intervertebral disc structurally consists of three distinct regions; the inner NP
and the outer AF anchored to the vertebral body by two endplates [22]. As previously
mentioned, the NP is the gel-like inner core, surrounded by the 15-25 rings, or lamellae,
of the AF [24]. The cartilaginous endplate is primarily comprised of hyaline cartilage
fibers which run parallel to the vertebral body [23]. The endplate has the highest cell
density for any of the three regions of the IVD. Cell density in the vertebral endplate has
been estimated to number around 15000 cells/mm3 [25]. Additionally, the endplate
performs two main functions; by providing blood flow to the IVD, the endplate is
responsible for providing nutrients to, and removing waste from the intervertebral disc
[26].
The annulus fibrosus (AF) is the ring-like structure surrounding the nucleus
pulposus (NP) [22]. The cells in the AF are most similar to fibroblasts, although they
have been referred to as fibrochondrocytes because of their production of both Type I and
II collagen [2] [5]. While the cells produce both Type I and II collagen, the AF is
primarily composed of Type I collagen [23]. The Type I collagen produced by the AF
cells forms fibers and eventually rings that concentrically surround the NP [24]. The cell
density of the AF is lower than the vertebral endplate, with cells numbering around 9000
cells/mm3 [25].
In the center of the IVD is the nucleus puposus (NP), the gel-like, hydrated central
region. The NP is composed of several components including large quantities of
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proteoglycans, specifically aggrecan and hyaluronan. Additionally, sulfated
glycosaminoglycans (GAGs) including chondroitin sulfate (CS) and keratin sulfate allow
the NP tissue to imbibe water and bear compressive loads [23]. The cells of the NP differ
from those in the AF, in that they can be described as chondrocyte-like. These cells
express markers for chondrocyte-like cells specifically for components like Type II
collagen, aggrecan and the mRNA marker Sox-9 [27]. NP cells are chondrocyte-like
producing a ratio of proteoglycans to collagen of approximately 27:1 in healthy NP
tissue, while in normal cartilage this ratio is approximately 2:1 [28]. Additionally, the cell
density in the NP is the lowest of the three IVD regions, with cell densities estimated at
approximately 5000 cells/mm3 [25].
All three IVD components work together allow the spine to bear loads and
allowing vertebrae to move freely with respect to one another [22]. The NP and AF
specifically work together to absorb loads. The NP is designed to bear compressive loads,
bulging outwards and pressing radially on the AF, placing it in circumferential tension
[29] [30]. A number of individuals have characterized the native NP and AF tissue in
both tension and compression. A summary of the modulus values for the NP and AF in
tension and compression can be found in Table 1. It is important to note that the values
reported correspond to the function of each tissue; specifically tension values are reported
for AF while compressive values are reported for native NP tissue.
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Table 1: A summary of the compressive and tensile modulus for native IVD tissue
(Adapted from Nerurkar et al [26])
Confined Compression
Uniaxial Tension (toe/linear)
Biaxial Tension, fixed
(toe/linear)

NP
1.0
MPa*
---

AF
440-750
kPa**
2.5/18-45
MPa
9.8/27.2 MPa

---

Reference
[31]* [32]** [33]** [34]**
[35] [36] [37] [38] [39] [40]
[41]
[42]

2.3 – Intervertebral Disc Degeneration
2.3.1 – Prevalence and Causes
Lower back pain is one of the most common medical problems, affecting nearly
80% of the adults in the United States at some point in their lifetime and costing
approximately $90 billion annually in healthcare costs [1] [2] [3] [4]. More specifically,
degenerative disc disease (DDD), which encompasses the spectrum of IVD degeneration
problems, affects 12 million individuals in the United States and accounts for
approximately $50 billion annually in health care costs [43].
There are a number of factors that can lead to lower back pain and disc
degeneration. It has been reported that smoking, intense vibrations and poor nutrient
diffusion into the disc tissue can lead to degeneration of healthy disc tissue [44] [45] [46].
Poor nutrient diffusion into disc tissue has been attributed to calcification of the vertebral
endplates, which slows the rate of nutrient diffusion into the disc tissue and leading to
DDD [47]. As the viable cell population within the disc tissue begins to fall, the
metabolic processes within the tissue shift from anabolic to catabolic, further aiding in
the degeneration of IVD tissue [5] [6]. Grad et al have called degeneration of the IVD
“premature aging” referring to how these processes eventually happen naturally as the
9

body ages, however appear to be happening earlier than normal in what was once healthy
IVD tissue [23].
As the IVD disc ages, there is a decrease in the number of proteoglycans available
in the tissue, specifically in the NP of the IVD. The aggrecan within the NP can become
fragmented and diffuse from the NP into surrounding tissues [48]. There is evidence that
point to catabolic processes, specifically enzymatic degradation of the IVD tissue that
leads to the fragmentation of both aggrecan and collagen in the NP. Enzymes families
including cathepsins, matrix metalloproteinases (MMPs) and aggrecanases appear to be
responsible for the increase in catabolic processes within the IVD [49] [50]. The fall in
aggrecan and collagen leads to a decrease in the amount of glycosaminoglycans (GAGs)
within the IVD [49]. The GAGs within the NP aid in the intake of water and nutrients
into the IVD, therefore a decrease in the GAG population causes dehydration, and
subsequently a decrease in the osmotic pressure of the NP [23] [49].
Dehydration of the NP causes a transformation from a gel-like structure to one
that is more fibrous, and this affects the ability of the NP to bear compressive loads [7].
The inability of the NP to bear compressive loads places unusual stresses on both the
vertebral endplate and AF [51]. These stresses on the vertebral endplate and the AF can
lead to bulging and herniation of the IVD. A herniated disc occurs when the inner NP
breaks through the lamellae of the AF, penetrating beyond the AF [30]. Examination of
herniated IVD show that the NP has migrated through existing tears in the AF, likely due
to the extraneous loads placed on the AF from NP dehydration [52]. The herniated IVD
placed pressure on the spinal cord, leading to pain and causing an inflammatory response
from the body [53] [54].
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2.3.2 – Current Treatments
Treatments for lower back pain and DDD can be broken into two categories,
conservative treatments and surgical intervention. Conservative treatment involves
mitigating the pain caused by degenerated, bulging or herniated IVD. Physical therapy
can be used as a non-medicinal route for the treatment of lower back pain. Physical
therapies may involve the use of heat and massaging of the area to alleviate some of the
pain. If medicinal routes are pursued, the use of anti-inflammatory, analgesic and muscle
relaxants may be used to reduce pain in the area. As a minimally invasive conservative
treatment, the injection of corticosteroid medication can be used to reduce pain in the
area [49] [8].
2.3.2.1 - Discectomy
When conservative treatments have failed, surgical options including lumbar
spinal fusion and discectomy can be considered [8]. The prevalence of spinal fusion
surgery is reported to be approximately 135.5 cases per 100,000 adults and costs an
estimated $82,000 per patient [55]. Discectomy is a procedure that aims to remove one
part of the IVD, rather than removal of the entire disc. In discectomy, the part of the IVD
that is pressing against the spinal cord, and hence the source of pain, is removed to ease
the patient’s pain [30]. Although discectomy is able to reduce pain in the short term, the
long-term results are more questionable. Bohlman et al report that discectomy has a
deleterious affect on the load bearing capabilities of the IVD which ultimately causes the
patient’s pain to return [56].
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2.3.2.2 – Spinal Fusion
A second surgical option for patients who experience pain from DDD is lumbar
spinal fusion surgery. Lumbar spinal fusion is a surgery that aims to remove the entire
IVD and fuse the two adjacent vertebrae, eliminating movement across that segment of
the spine. In addition to the removal of the entire IVD, a bone graft is often used to aid in
the fusion of the vertebrae [30]. The goal of spinal fusion is that by removal of the entire
IVD and stopping the movement across the joint the patients pain will be eliminated [57].
There is evidence however, that spinal fusion may also not fully alleviate pain in long
term studies. A study performed by Lee suggests that both discectomy and spinal fusion
accelerate the rate at which degeneration in adjacent IVDs takes place which may cause
the patients future pain [58].
2.3.2.3 – Disc Replacement
While spinal fusion seeks to stop pain by removing motion across that segment of
spine, others have investigated removing the entire IVD and replacing the disc with a
prosthesis that is able to replicate the properties of the native IVD tissue allowing the
patient to maintain their mobility of the segment. There are currently two Food and Drug
Administration (FDA) approved devices for the total replacement of degenerated IVDs.
Namely the prosthetics are the SB Charitè III (DePuy Spine, Raynham, MA) and the
ProDisc (Synthes, Inc., Paoli, PA), Figure 3 and Figure 4 respectively [10].
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Figure 3: The FDA approved SB Charitè III total disc replacement prosthetic [59]

Figure 4: The FDA approved ProDisc total disc replacement prosthetic [60]

The SB Charitè III has two main parts. The inner core of the prosthetic is a freefloating ultra high molecular weight polyethylene (UHMWPE) oval shaped insert. The
core floats between two metallic endplates. The endplates are made of a cobaltchromium-molybdenum (CoCrMo) alloy. The prosthetic is held in place by twelve teeth
(six on each metallic endplate) that anchor the implant to the adjacent intervertebral
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bodies. The flat shape of the endplate and the CoCrMo allow is designed to limit the
amount of wear and debris from the UHMWPE core [61].
The ProDisc prosthetic is similar in that it too has a UHMWPE, however the core
ProDisc is anchored to the lower metallic endplate of the device. Additionally, the
ProDisc features a central fin that servers to anchor the device into the adjacent vertebral
bodies, compared with the teeth of the SB Charitè III. The fin is designed to promote
bone ingrowth into the prosthetic and therefore securely anchor the device to adjacent
vertebral bodies [61].
When compared to spinal fusion surgery, the patients who received total disc
replacement with a prosthetic device have reported shorter recovery times and lower
initial pain [62] [63]. Although prosthetics reported this advantage, there are several
problems that occur when total disc replacement is used. Several groups have reported
that these prosthetic devices are prone to loosening and possible extrusion [64] [65] [66].
In addition, the polyethylene core of both prosthetic devices is prone to wear and
cracking from the stresses experienced between vertebrae. Cracking of the polyethylene
core can ultimately lead to the failure of the device, which then must be extracted and
replaced [67] [68] [69]. These problems have caused some to question the longevity of
such total disc replacement prosthetics [10].
2.3.2.4 – Nucleus Replacement
In addition to total disc replacement surgery, the prosthetic disc nucleus (PDN)
(Raymedica, Bloomington, MN) device that is FDA approved for the replacement of the
NP alone [10]. The PDN, seen in Figure 5, is used when the AF is still structurally sound,
however the inner NP is beginning to degenerate [10] [70]. The PDN makes use of an
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inner hydrogel core, covered in a biodegradable mesh that prevents over swelling of the
device. The goal of using the PDN is to mimic the natural mechanical properties of native
NP tissue [10] [71]. Specifically, a hydrogel is a polymeric material that has the capacity
to imbibe water, and remain hydrated in its application, while the polymeric material
itself remains intact [72]. The inner hydrogel allows the PDN to maintain a fluid like
structure, allowing it to imbibe water, nutrients and function similar to native NP tissue
[71].

Figure 5: The FDA approved prosthetic disc nucleus (PDN) for the replacement of
the NP alone [70]

The advantage to using a prosthetic like the PDN is that the surgery is far less
invasive than surgery to remove the entire disc, such as spinal fusion and total disc
replacement procedures [73]. Although surgery to implant the PDN is less invasive, it
often times damages the AF, which elicits an inflammatory response from the body and
can begin the disc degeneration processes, negating the effect of nucleus replacement
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altogether [10]. Additionally, several groups have reported that patients who received the
PDN experienced problems with device migration and ultimately expulsion from the site
of implantation, a problem similar to the other prosthetic devices being used [74] [61].
2.4 – Tissue Engineering
Tissue engineering is a promising area in both biomaterials and NP replacement
research. A biomaterial has been defined by D.F. Williams as “material intended to
interface with biological systems to evaluate, treat, augment or replace any tissue, organ
or function of the body” [75]. Tissue engineering itself makes use of biomaterials
integrated with cells with the overall goal being to repair and or regenerate new tissues
within the body. The cells synthesize new components, specifically those found in the
extracellular matrix (ECM) of the tissue [9]. The ECM components of a tissue are
composed of proteins and glycoproteins that can be found in immediate vicinity of the
tissue [75]. Of the cells that are used for tissue engineering, the stem cell shows
applicability to a wide range of applications because it is found to be both
immunologically “invisible” to the patient and can be driven to differentiate into number
of different tissues. In the area of IVD repair and replacement, the mesenchymal stem cell
(MSC) is particularly important for its ability form bone, muscle and in the case of the
IVD, cartilage tissue [9].
The tissue engineer often makes use of a scaffold, or matrix, when repairing
tissues. The scaffold is simply the three dimensional biomaterial in which the cells and
ECM components are embedded [75]. Lanza, Langer and Vacanti provide a number of
properties for the tissue engineering scaffold that provide flexibility to design a system
that will accurately replicate the physiological properties of tissues when implanted in the
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body. Of these properties, the scaffold can be either permanent (non-biodegradable) or
temporary (biodegradable). The scaffold can be designed from a number of materials
including synthetic, natural or some combination thereof (semi-synthetic). The scaffold
can be designed not only to interact with cells embedded within, but with cells that
surround the site of implantation. As such, the scaffold can be designed to release growth
factors, proteins and other ECM components that allow for a number of cellular events to
occur, including stem cell differentiation and cellular attachment [9].
2.4.1 – Tissue Engineering of the NP and AF
Tissue engineering provides a way to repair and moreover, replace damaged
tissues within the body. Of these important areas is the repair and replacement of IVD
tissue. Tissue engineering of the AF and NP however proves problematic because of the
different cell types and structures found in the AF and NP. While the AF can be
described as a fibrochondrocyte, producing primarily type I collagen, the NP remains
more chondrocyte like producing primarily type II collagen and a wide variety of GAGs
[23] [26] [27]. These differences have made the simultaneous design of a complete IVD
difficult and have caused researchers to focus on the replacement of only one component
of the IVD rather than both AF and NP.
Several researchers have developed scaffolds for the replacement of the NP based
on natural polymers. Among these are polymer scaffolds made of hyaluronic acid (HA).
Revell et al replaced the NP with two injectable HA scaffolds (HYAFF 120 and HYADD
3). These scaffolds were able to take the shape of the defect when implanted in vivo into a
porcine spine. Additionally, the scaffold was embedded with stem cells derived from
bone marrow and the scaffold maintained cell viability and promoted the production of
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ECM components [76]. Cloyd et al developed HA hydrogels for the replacement of NP
tissue and compared the mechanical properties to that of semi-synthetic poly(ethylene
glycol) (PEG) grafted chitosan hydrogels and native NP tissue. Cloyd et al found that the
hydrogels showed similar properties to that of native NP tissue and therefore would make
a good candidate for a NP tissue engineering scaffold [77]. Nesti and Li also developed a
HA based scaffold for replacement of the NP. Their HA NP replacement scaffold was
enveloped with a biodegradable nano-fiber region that resembles the AF. When
embedded with human MSCs in vitro for four weeks the cells differentiated into
chondrocytes, exhibiting biochemical markers for NP cells. Nesti and Li concluded that
this tissue engineered IVD replacement with HA showed promise after in vitro testing
[78].
Alginate is a second natural scaffold that has been investigated for NP
replacement. Chou et al developed a photo-crosslinked alginate matrix for the
replacement of the NP. The scaffold was tested both in vitro and in vivo and shown to
produce ECM components indicative of NP cells, specifically in the production of
aggrecan and type II collagen. Although the matrix showed more ECM production in
vivo, a fibrous encapsulation was found to have surrounded the scaffold [79]. Mizuno et
al performed trials with a calcium alginate scaffold for NP replacement using athymic
mice. The alginate scaffold was seeded with NP cells and then the scaffold was injected
into the NP. After 12 weeks this scaffold showed biochemical markers for ECM
production including type II collagen, consistent with native NP tissue [80]. A number of
other researchers have used alginate scaffolds embedded with cells for replacement of the
NP. The cell types included human MSCs, canine and rabbit NP cells and were found to
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either form chondrocyte like cells and or begin the production of ECM components that
would compare to native NP tissue [81] [82] [83] [84] [85] [86].
Collagen is another natural biomaterial that has been investigated for the repair of
the NP. Wilke et al developed a scaffold comprised of type I collagen for the replacement
of the NP. Although the material performed successfully when implanted into bovine
lumbar vertebrae in vivo, the material was not embedded with any cells. Wilke et al also
cited problems with expulsion of their polymer when it was tested over longer periods of
time [11]. Additional authors have investigated the use of collagen scaffolds, including
those combined with HA and human or bovine NP cells to induce ECM production. In
these cases ECM production mimicked that of the native IVD tissue, with both type I and
II collagen being seen, along with aggrecan and proteoglycans [87] [88] [89]. Halloran et
al has also developed an atellocollagen scaffold crosslinked with microbial
transglutaminase (mTGase). The scaffold produced similar mechanical integrity and
produced ECM components when embedded with bovine NP cells, although excess
concentrations of the crosslinking agent adversely affected the viability of cells [90].
Chitosan has been used as another natural scaffold for NP replacement. Roughley
et al developed a chitosan based hydrogel for the retention of GAGs and proteoglycans
produced by embedded bovine NP cells. The cells were successfully able to produce
ECM components when tested in vitro and these components were then successfully
retained by the chitosan scaffold [91]. Mwale et al also developed chitosan polymers for
IVD repair; these injectable polymers included both chitosan chloride and chitosan
glutamate crosslinked with genipin. The polymer was tested and proved biocompatibility
when injected into mice and was also able to successfully harbor IVD cells. Additionally,
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the polymer was injected into cadaver spines and found to completely fill defects in the
IVD and was not expelled from the spine [92].
Calcium polyphosphate, another natural polymer, has been investigated construct
for the growth and formation of a tissue engineering scaffold for nucleus replacement
because of its porous nature. In one study, Séguin et al seeded a calcium polyphosphate
scaffold with bovine NP cells and tested for ECM production and mechanical strength in
vitro. The production of ECM showed components that would be indicative of native NP
tissue while the compressive strength of the scaffold was found to be comparable to the
native tissue [93]. Hamilton et al investigated the use of calcium polyphosphate for the
replacement both the NP and the vertebral end plate. This design was chosen to enhance
the integration of the scaffold with the vertebral body. In this study calcium
polyphosphate was seeded with bovine NP cells after chondrocytes had deposited a layer
of cartilage atop the calcium polyphosphate construct. After 8 weeks, the scaffold formed
ECM consistent with native tissues, and the addition of a cartilaginous layer enhanced
cellular attachment of the NP cells, ultimately leading to greater ECM production [94].
Combinations of these natural materials have also been investigated in an attempt
to create a multicomponent scaffold for the replacement of IVD tissues. Yang et al
developed a tri-polymer scaffold for the replacement of the NP and examined these
results in vitro. The scaffold was comprised of gelatin, chondroitin-6-sulfate and HA and
was seeded with human NP cells. Over a four week time period the scaffold maintained
cellular viability and showed biochemical markers consistent with native NP tissue [95].
Additionally, Li et al has investigated a multicomponent scaffold made from type II
collagen, HA and chondroitin-6-sulfate. This scaffold was enhanced by crosslinked using
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both 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide (EDC) and N-hydroxysuccinimide
(NHS). The scaffold was found to exhibit similar properties to the native NP tissue,
specifically in that the components chosen for the scaffold itself closely resembled those
found in the native tissue [96].
In addition to the natural polymeric materials investigated for IVD tissue
engineering, there are a number of synthetic materials that have been examined for their
properties and potential to replace the IVD. One such synthetic polymer blend if the
polyvinyl alcohol (PVA) and polyvinyl pyrrolidone (PVP) copolymer. Thomas et al
developed a PVA-PVP copolymer that was modifiable through freeze/thaw cycles and
could be tailored to the properties of the NP. These PVA-PVP hydrogels, when reswollen, were found to have increasing compressive strength as the amount of
dehydration increased. Additionally, through cadaver testing the polymer exhibited
comparable compressive strength to native tissues [97]. Joshi et al also developed a PVAPVP copolymer for the replacement of the NP and tested its mechanical properties. The
polymer exhibited comparable properties to native tissue in both confined and unconfined
compression testing and cadaver testing [98].
Polyethylene glycol (PEG) is another synthetic hydrogel that could be used for the
replacement of the NP. Saldanha et al developed a hydrogel scaffold from PEG for the
replacement of NP tissue. The scaffold was embedded with MSCs, and the scaffold was
tested for the viability of these cells. This synthetic scaffold was successfully able to
promote the viability of MSCs for the replacement of NP tissue [99].
Several researchers have investigated the use of poly (L-lactide-co-glycolide)
(PLGA) and poly (L-lactic acid) (PLLA) for NP replacement and ECM production. Ruan
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et al developed a scaffold base on PLGA for NP replacement. The scaffold was tested in
vivo with NP cells. The scaffold was implanted into a canine disc and was able to
maintain disc height and stability after implantation and the scaffold also helped to
prevent further degeneration of the IVD [100]. Richardson et al developed a scaffold of
PLLA to promote the differentiation and viability of human MSCs into chondrocytes. For
this study, the MSCs were first differentiated with the transcription factor Sox-9 and then
seeded onto the PLLA scaffold. Once embedded in the scaffold the cells maintained their
chondrocyte phenotype and produced ECM components including type II collagen and
aggrecan, major components of native NP tissue [101].
Among some novel synthetic scaffolds for NP replacement is the use of bioactive
glass. Gan et al developed a bioactive glass substrate for the proliferation of rabbit NP
cells and subsequent ECM deposition. Researchers have found that the calcium rich
region of the bioactive glass aided in cellular attachment and ECM deposition.
Additionally, the ECM components produced mimicked those produced by native NP
tissue [102].
While there have been many advances in tissue engineering of the IVD, a number
of researchers have expressed problems with expulsion from the area and migration of
the implants. This is especially prevalent with this scaffolds that are able to be injected
into the area and cure in situ making the need for a tissue adhesive used in conjunction
with tissue engineering scaffolds a paramount concern for biomedical engineers [10]
[11].
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2.4.2 – Poly (N-isopropyl acrylamide) for Tissue Engineering Applications
One of the most interesting polymeric materials currently under investigation for
tissue engineering applications is poly (N-isopropyl acrylamide) (PNIPAAm), shown in
Figure 6. Many hydrocarbons experience a lower critical solution temperature (LCST),
the lowest temperature in which the polymer and the solvent are miscible in one another.
PNIPAAm, unlike other hydrocarbons, is susceptible to a temperature dependent phase
transition that occurs between 31-32°C, the reported LCST of PNIPAAm [17]. Below its
LCST, PNIPAAm forms a number of hydrogen bonds with water. As the temperature is
increased above the LCST, these hydrogen bonds are broken as the polymer under goes a
conformational change, ultimately leading to its decreased miscibility in water [103].
Undergoing this conformational change, PNIPAAm begins to form more hydrophobic
interactions with the polymer side chain groups. These interactions cause the PNIPAAm
polymer chains to aggregate into a single mass, thereby “self-assembling” into the
hydrogel state [17]. Because this phase transition happens above the LCST temperature
of 32°C, PNIPAAm is an excellent scaffold for use in a number of tissue engineering
applications within the body for its ability to be implanted minimally invasively and
subsequently self assemble at body temperature.
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Figure 6: PNIPAAm molecular structure [17]

PNIPAAm has been used in a number of broad tissue engineering applications.
Akiyama et al developed a PNIPAAm copolymer scaffold including polystyrene (PS) for
cellular attachment. Attachment of the cells was controlled by temperature, where at high
temperatures with the PNIPAAm-PS hydrogel was self-assembled the cells would remain
attached and when the polymer was dropped below its LCST, the cells would detach
from the scaffold [104]. Kim and Healy developed a PNIPAAm scaffold with acrylic acid
(AAc) for tissue engineering applications. This scaffold contained a peptide sequence
recognizable by MMPs while allowed for enzymatic degradation and have minimal affect
on the thermosensitve response of the polymer at its LCST [105]. In addition, Ohya et al
developed a PNIPAAm-HA scaffold for various tissue engineering applications. This
scaffold was found to inhibit the attachment of cells when it was used as a coating on
surfaces, although this was likely due to hydrophobic interactions from the side chains of
HA [106].
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In addition to general tissue engineering applications, a number of researchers
have developed PNIPAAm based scaffold for the repair of cartilaginous tissues. Chen et
al developed a PNIPAAm-chitosan scaffold for the replacement and repair of cartilage,
specifically the meniscus. The introduction of chitosan allowed for increased mechanical
properties over the homopolymer. Testing in vivo showed that the scaffold was noncytotoxic and demonstrated the ability to maintain cellular viability [107]. Stile et al
examined PNIPAAm and PNIPAAm-AAc scaffold for cartilage tissue engineering.
When this scaffold was embedded with bovine chondrocytes it promoted both
proliferation and cellular viability for four weeks in vitro. The authors mention that this
polymer could be outfitted with enzymatically degradable crosslinks and that the polymer
demonstrated promising biocompatibility in preliminary in vivo studies [108].
In the area of the spine, researchers have investigated the use of PNIPAAm based
scaffolds for the repair of spinal cord injuries. Comolli et al investigated a PNIPAAmPEG scaffold for repairing spinal cord injuries. Again, the scaffold was easily tailored to
be applicable for number of applications and had the ability to release bioactive trophic
factors for a four-week period at physiological conditions. Additionally, this scaffold
promoted the attachment and proliferation of MSCs within [109]. Conova et al developed
both a PNIPAAm-g-PEG and PNIPAAm-g-methylcellulose (MC) scaffold for spinal
cord repair. The scaffold was tested in vivo using rats and found to completely fill the
defect when injected. The PNIPAAm-PEG scaffold was found to support cell
proliferation when tested in vivo, and while the PNIPAAm-MC scaffold was not tested in
vivo, it was expected to perform similarly. Additionally, this scaffold was able to

25

successfully deliver neurotropic factors, a key component to the regeneration of axons in
the spinal cord [110].
Few researchers have investigated the use of PNIPAAm for the repair and
regeneration of damaged IVDs. Vernengo et al developed an injectable PNIPAAm-PEG
scaffold for the repair of NP tissue. With the addition of PEG to this polymer, it was able
to imbibe more water than the homopolymer. When the polymer was allowed to swell for
60 days it exhibited mechanical properties that were similar to those of native disc tissues
[111]. The authors of this study also incorporated poly (ethylene imine) (PEI) into the
polymer. Once the polymer was injected into the defect, an injection of gluteraldehyde
was administered to prevent expulsion of the implant. This adhesive works via aldehydeamine chemistry, which has applications in a number of different tissue engineering areas
[112].
2.5 – Bioadhesives
2.5.1 – Bioadhesive Overview
Bioadhesives are of specific interest to the tissue engineer for a variety of
applications. Specifically, a bioadhesive is any component that is used in a medical
application for the purposes of adhering two tissues together [75]. The field bioadhesive
is so broad that it encompasses many materials, and like biomaterials, can be natural,
synthetic or some combination thereof.
2.5.2 – Cyanoacrylates
One widely used synthetic bioadhesive is the cyanoacrylate adhesive, seen below
in the varying forms available as Figure 7. Cyanoacrylate adhesives are widely used in
medical applications for wound closure, however they have found some use in surgical
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applications, specifically hemostasis and fistula repairs [113] [114]. In addition to these
surgical applications, Pollak and White performed a review of the use of cyanoacrylate
adhesives and their use for embolization within the body [115].

Figure 7: A variety of the commercially available cyanoacrylate bioadhesives [116]

A number of authors have investigated the use of cyanoacrylate adhesives for an
number of different applications. Toriumi et al investigated the use of cyanoacrylate
adhesives for attaching different grafts within the body, and examined how the chain
length of the adhesive affected the histology of cells. The authors examined attaching a
bone graft to the cartilage of rabbit ears with both ethyl-2-cyanoacrylate (Krazy Glue)
and butyl-2-cyanoacrylate (Histoacryl). The authors found that the longer (butyl)
cyanoacrylate adhesives have a decreased inflammatory and foreign body response from
cells in addition to being less toxic to tissues [117]. The shorter (methyl and ethyl)
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cyanoacrylates are potentially toxic because of their quick degradation into harmful
byproducts, including formaldehyde [118].
Ekelund and Nilsson examined the use of cyanoacrylate adhesives and their
possible use in healing bone fractures. This study found that the use of cyanoacrylate
adhesives causes a severe inflammatory response from the body, and its slow degradation
rate caused it to remain within the body weeks after use. When the authors tested the use
of the adhesive in vivo they found that in some instances the adhesive can completely
inhibit the formation of new bone [119]. In addition to bone repair, the use of
cyanoacrylates for repairing cartilage has also been examined. Reckers et al investigated
the use of cyanoacrylates for repair of the meniscus in vivo with rabbits. The
cyanoacrylates had such a negative effect, including severe inflammatory responses and
tissue necrosis, that it caused the early termination of experimentation [120].
There are several advantages to the use of cyanoacrylate adhesives;
cyanoacrylates are a strong adhesive with strength on the order of 1000 kPa and they
have markedly faster sealing times than other commercially available adhesives,
specifically fibrin glue [121] [122]. While these advantages make cyanoacrylates an
attractive choice, they have several severe disadvantages that make their use very limited.
Cyanoacrylates have two main toxic degradation, cyanoacetate and formaldehyde, which
while not a problem for external wound closure, may cause a problem in other internal
application. While the rate of the degradation can be controlled by chain length, the
longer the side chains the slower the degradation, all cyanoacrylates form these two
byproducts [116]. The polymerization of cyanoacrylates, allowing the adhesion to take
place, forms via an exothermic reaction which can damage tissues and cause burns [123].
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Finally, cyanoacrylate adhesives have been associated with severe tissue necrosis when
tested in vivo which is possibly attributed to the oxidation and ultimate lysis of cell walls
[124]. While cyanoacrylates have superior strength over other adhesives, their poor
biocompatibility limits their use in many applications.
2.5.3 – Fibrin Adhesives
Fibrin adhesives represent a group of natural adhesives and is comprised of
fibrinogen and thrombin. The two components of the fibrin adhesive are mixed at the site
of adhesion and the adhesive mimics the final stages of the blood clotting cascade [125].
The current applications for fibrin adhesives are similar to those of cyanoacrylate
adhesives including uses for wound closure. Fibrin adhesives are also used for a number
of surgical applications including hemostasis and tissue adhesion [114].
As with cyanoacrylate adhesives, a number of authors have investigated
alternative uses for fibrin adhesives. In comparison with the cyanoacrylate adhesive for
meniscus repair, Reckers et al investigated the use of fibrin in vivo using rabbits. The
rabbits treated with fibrin adhesives had scores for inflammatory response, fever, distance
walked, diet refusal and knee extension comparable to meniscuses that were secured
using sutures. Although this was comparable, the authors found that the fibrin adhesives
impaired the spread of cells changing the appearance of the meniscus over knees secured
with sutures [120]. Brittberg et al also examined the use of fibrin adhesives for the repair
of cartilage using rabbit knees. These authors found that the adhesive was a poor scaffold
in vivo unable to promote cell proliferation and the adhesive was insufficient to fill large
defects in the cartilage. Additionally, the adhesive performed much more poorly than if
the defect had been sutured shut [126].
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A number of authors have investigated the development of fibrin adhesive
scaffolds for tissue engineering applications. Bensaïd et al developed a scaffold
consisting of fibrin adhesive that could be used to deliver human MSCs. This scaffold
successfully promoted the growth and proliferation of human MSCs, however when
implanted into mice, the cells migrated beyond the scaffolding. This indicated that this
fibrin scaffold would perform better as a delivery vehicle for cells [127]. Christman et al
examined a fibrin scaffold for the treatment of myocardial infraction. This scaffolding
supported myoblast cell growth and proliferation in vitro. In addition, when the cells
were transplanted into rats using the fibrin adhesive the viability of the cells and blood
flow to the area were both increased [128]. Yamada et al also developed a fibrin scaffold,
including β-tricalcium phosphate, to encapsulated MSCs for bone repair and
regeneration. The fibrin adhesive was shown to promote the viability and proliferation of
MSCs and produced bone only when the β-tricalcium phosphate was included into the
mixture. After 8 weeks in vivo using rats, the scaffold successfully produced bone tissue
[129]. Similarly, Lee et al showed that fibrin adhesive combined with macroporous
biphasic calcium phosphate and rat MSCs successfully promoted bone growth [130].
While the biocompatibility, namely the cell encapsulation ability, of fibrin
adhesive is an advantage over cyanoacrylate adhesives; fibrin adhesives have relatively
poor strength. Chivers and Wolowacz showed that the strength of cyanoacrylate
adhesives is approximately 200 times stronger than joints sealed with fibrin adhesive
[121]. A comparison of these adhesive strengths can be seen in Table 2.
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Table 2: Relative adhesive strength of cyanoacrylate adhesive and fibrin adhesive
adhered to cartilage in both lap and butt joints [121]
Butt Joint Strength (kPa)
Lap Joint Strength (kPa)

Cyanoacrylate Fibrin
1000
4.9
700
---

2.5.4 – Aldehyde Based Adhesives
In addition to the two commonly used adhesives, fibrin and cyanoacrylates, there
are a number of innovative aldehyde based adhesives developed that are able to react
with tissues via a Schiff’s Base reaction. A Schiff’s base reaction takes place between
aldehyde groups on the adhesive and amines located on the tissue surface, forming one
covalent bond and the production of water, seen below as Equation 1 [131].

Equation 1: A Schiff's base reaction between aldehyde groups on the adhesive and
amines on tissues, producing water and a covalent bond [131]
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One aldehyde adhesive currently in use is the glutaraldehyde adhesive (produced
under the trade name BioGlue) seen in Figure 8. BioGlue is an injectable adhesive
consisting of two components, specifically bovine serum albumin (BSA) and
glutaraldehyde. Currently, BioGlue is approved by the FDA for the repair of larger blood
vessels (i.e. aorta) and hemostasis [132]. The limited area of use is because the long term
effects of BioGlue on the body are not well understood and require further investigation
[133].
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Figure 8: Glutaraldehyde, the adhesive component of the commercially produced
BioGlue [134]

Several researchers have investigated the use of glutaraldehyde adhesives in
applications outside of what is currently approved. Kilmo et al performed a clinical trial
using BioGlue to seal surgical wounds in the area of the cranium and spinal cord. The use
of BioGlue in this area was found to cause a severe inflammatory responses and
complications, causing the authors to discourage the use of BioGlue in these applications
[135]. Gaberel et al retrospectively studied patients who underwent craniotomies where
BioGlue was used as the sealant. The authors here linked the use of BioGlue to increased
likelihood of surgical site infection, likely due to the inflammatory response to the
adhesive [136]. Hidas et al performed a clinical trial in the use of BioGlue for renal
surgeries. The authors found that in this case, BioGlue successfully reduced both the
amount of blood lost, thereby decreasing the need for transfusions, and reduced the
prevalence of urinary fistula formation. These results were found to be comparable to the
traditional suturing technique [137].
In addition to the clinical trials, Fürst and Banerjee examined the in vivo use of
BioGlue and its cytotoxic effects over cultured cells and various tissues. In this study,
both human embryo fibroblasts and mouse myoblasts were used along with cells from
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rabbit heart, lung and liver tissues. In the rabbit tissue studies, fibrin was used as a
control. The authors found that the glutaraldehyde released from the BioGlue negatively
affected the viability of cultured cells. In addition, when BioGlue was applied to rabbit
lung and liver tissues, a severe inflammatory response was seen along with tissue
necrosis. The authors note that these effects are less severe in the approved applications
because the aorta is largely ECM components with lower cellular populations. The
authors of this study concluded that the use of glutaraldehyde based adhesives should be
limited to the current aortic applications because of the deleterious effects seen in other
tissues [20]. St. Clair et al has also noted the cytotoxicity of aldehyde based adhesives,
namely glutaraldehyde in their studies [21].
In addition to glutaraldehyde, a number of researchers have developed novel
bioadhesives that utilize aldehyde groups for bond with tissues. Murakami et al
developed a polymeric micelle composed of poly (ethylene glycol) and poly (DL-lactide)
(PEG-PLA) terminated with aldehyde groups. The polymer in this study was known to be
non-cytotoxic, while the crosslinker used had poor tissue permeability theoretically
decrease possibly cytotoxic effects. The adhesive was evaluated for its hemostatic
capabilities in vivo and was able to successfully stop bleeding in a variety of different
applications. This novel adhesive performed similarly as a hemostatic agent when
compared to the commercially available Tisseel, a fibrin based bioadhesive [138].
In addition to artificial polymeric materials for bioadhesion, natural materials
have also been modified to form novel bioadhesives. Artzi et al developed an adhesive
polymer made from PEG and dextran, a naturally occurring polysaccharide. In this study,
the dextran was functionalized with aldehyde groups, which could be tailored to the
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specific degree of adhesion required. The biocompatibility of the system was tested with
rats in vivo and the researchers determined that there was inflammatory response from the
adhesive that increased as the number of aldehyde groups on the functionalized dextran
increased [12]. Shazly et al developed a hydrogel system that was a combination of both
star PEG and a dextran aldehyde adhesive. The dextran aldehyde was synthesized
through an oxidation reaction and reacted with tissues via the Schiff’s base reaction. The
adhesion of the polymer was tested on intestinal puncture wounds in vitro on its ability to
resist bursting when pressure was increased, and performed successfully. The researchers
noted that although increased aldehyde content can increase adhesion, steric interactions
between adjacent aldehyde groups limit the adhesive ability. Additionally, the researchers
noted that as the aldehyde content was increased, more interactions with amines took
place decreasing the time for the polymer to form a consistent gel [13]. Bhatia et al also
examined cytotoxic effects of a PEG amine and dextran aldehyde polymer adhesive in
comparison with cyanoacrylate adhesive. In this study, mouse fibroblasts were placed in
direct contact with the adhesive, which was found to be non-cytotoxic to cells, while
cyanoacrylate adhesive was toxic to the same cells. Additionally, this dextran aldehyde
adhesive did not cause an inflammatory response when placed in contact with mouse
peritoneal macrophages [14].
Several researchers have also investigated chondroitin sulfate, a naturally
occurring polysaccharide similar to dextran, as a novel bioadhesive. Reyes et al
developed a chondroitin sulfate adhesive for sealing corneal incisions and tested ex vivo.
The chondroitin sulfate was functionalized with aldehyde groups via an oxidation
reaction and the adhesive was used to seal incisions to the cornea in comparison to
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incisions sealed with sutures. When the pressure of the incision was examined, the
adhesive sealed incisions were able to withstand twice to four times the amount of
pressure as incisions sealed with sutures. Although the adhesive performed better than
incisions sealed with sutures, the biocompatibility of this adhesive was not examined by
the authors [15]. Wang et al also developed a chondroitin sulfate based adhesive,
functionalized with both aldehyde and methacrylate groups, contained within a poly
(ethylene glycol) diacrylate (PEGDA) hydrogel matrix. In vitro testing was performed on
chondrocytes in direct contact with the chondroitin sulfate adhesive, which was applied
using a brush. Chondrocytes were viable when examined over a five-week period in
direct contact with the aldehyde-based adhesive, and incorporation of the hydrogel
allowed the system to completely fill defects and increased ECM production by
embedded cells [16]. Although aldehyde based adhesive systems are novel, additional
researchers must investigate and address biocompatibility problems before future tissue
engineering applications can be examined.
2.6 – Summary of Work
There is a need for a novel bioadhesive polymer scaffold that can support cell
viability and encourage proliferation and differentiation not only in vitro, but also
ultimately in vivo. This work investigates the development of a novel bioadhesive
polymer that will be used to tissue engineer IVD tissue, specifically the NP. The polymer
is comprised of several novel components, allowing it to create the ideal scaffold for
repair and regeneration of damaged IVD tissues. This bioadhesive scaffold must
maintain the biocompatibility of commonly used fibrin adhesives, however this scaffold
needs to be stronger than the fibrin adhesive. Researchers have yet to develop a novel
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bioadhesive scaffold, capable of supporting cell life, for tissue engineering applications
relating to the IVD.
The proposed solution will include a polymer scaffold created of PNIPAAm
grafted with CS. The PNIPAAm will be utilized for its thermosensitive properties,
allowing the final scaffold to be implanted minimally invasively and to solidify in situ.
Grafting chondroitin sulfate onto the polymer backbone will allow the system to have
increased biocompatibility, decreased inflammatory response in the body, imbibe water,
nutrients, enzymatic degradation characteristics and aid in cell proliferation and
differentiation [18] [19]. Aldehyde functionalized chondroitin sulfate will serve as the
adhesive component of this system. In this case, the chondroitin sulfate will be modified
through an oxidation reaction, similar to that performed in Reyes et al, and will react with
amines on the tissue surface via a Schiff’s base reaction [15].
The ultimate goal of the scaffold and adhesive is to not only repair, but also
regenerate IVD tissue. Therefore, cells must be encapsulated into the system and the
cytotoxic effects of the aldehyde groups on the adhesive must be combatted. Lipid
vesicles, or liposomes, are small particles composed of a lipid bilayer that can
encapsulate a variety of materials. Liposomes have been used widely in many
applications, specifically drug delivery applications, and therefore should be able to
deliver ECM derivatives in our adhesive scaffold [139] [140] [141] [142]. Additionally,
the lipids can be chosen in such a way that they melt at body temperature, in order to
release the components within after adhesion has take place, but before cytotoxic events
can occur [142]. Gelatin, a widely available and low cost protein, will be loaded into each
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of the vesicles and has the ability to react with any remaining aldehyde groups via a
Schiff’s base reaction, preventing the cytotoxicity of the cells.
The final system will combine a PNIPAAm-CS copolymer, CS aldehyde, gelatin
loaded lipid vesicles and cells for a novel tissue engineering strategy to repair the NP of
the IVD. In this study, the adhesive strength, rheological properties, lower critical
solution temperature behavior, and biocompatibility were examined and quantified.
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Chapter 3
Materials and Methods
3.1 – Materials Synthesis and Characterization
3.1.1 – Poly (N-isopropylacrylamide) graft Chondroitin Sulfate Synthesis
Poly (N-isopropylacrylamide) graft chondroitin sulfate (PNIPAAm-g-CS) was
synthesized in a 1000:1 molar ratio by reacting N-isoproylacrylamide (NIPAAm)
monomer with chondroitin sulfate (CS) functionalized with methacrylate groups (mCS)
through a procedure previously developed at Rowan University [143]. Chondroitin
sulfate was functionalized using methacrylic anhydride (MAA) following a procedure
adapted from Bryant et al [144]. A 25:1 molar ratio of methacrylic anhydride to CS was
used resulting in a substitution of 0.1 methacrylate groups per repeat unit of CS, verified
previously using H1 nuclear magnetic resonance (NMR).
Methacrylated chondroitin sulfate was synthesized by dissolving 2 grams of CS
(Sigma Aldrich) in 8 mL of de-ionized (DI) water. Once dissolved, the pH of the reaction
mixture was corrected to 10 using 50% w/v sodium hydroxide (NaOH). When at the
correct pH, 0.298 mL of MAA was added, and the mixture reacted while shaking for 24
hours at 60°C. The reaction can be seen in Figure 9. The mCS was then precipitated in
300-400 mL of cold acetone, vacuum filtered, and dried overnight in a vacuum oven prior
to use.
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Figure 9: The reaction scheme for synthesizing mCS from CS and MAA [144]

NIPAAm (Acros) was first purified by dissolving in an excess amount of nhexane at 60°C while stirring periodically, then recrystallized in an explosion proof
freezer overnight. The recrystallized mixture was vacuum filtered and placed in the
vacuum oven overnight to remove excess n-hexane. Purified NIPAAm was stored in the
freezer prior to use.
PNIPAAm-g-CS was synthesized via redox polymerization by first dissolving 10
grams of NIPAAm and 2.209 g of mCS in 190 mL of DI water. The mixture was bubbled
with nitrogen gas for a minimum of 15 minutes to remove excess oxygen. Once oxygen
was removed, 0.8 mL of Tetramethylethylenediamine (TEMED) was added first, then
0.08 g of ammonium persulfate (APS) and the mixture was stirred vigorously for 15
seconds. The reaction was carried out for 24 hours under fluorescent lighting before
placing the mixture into a 37°C incubator to aggregate. The PNIPAAm-g-CS was
allowed to dialyze at 37°C for one week, with the PBS changed daily prior to
lyophilization. Once dry, the polymer was hydrated as a 5% (w/v) solution in phosphate
buffered saline (PBS) for use.
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3.1.2 - Chondroitin Sulfate Aldehyde Synthesis
Chondroitin sulfate was oxidized in the presence of sodium periodate using a
procedure similar to that presented in Reyes et al [15]. The oxidation allowed for the
formation of aldehyde groups on the CS backbone creating a novel bioadhesive, as seen
in Figure 10. Two grams of CS was dissolved in 40 mL of DI water and the mixture was
bubbled with nitrogen gas for a minimum of 5 minutes. Two grams of sodium periodate
were added and the reaction was carried out at room temperature in the dark while
stirring for six hours. To stop the reaction, 0.55 mL of ethylene glycol was added to the
reaction mixture and the mixture was allowed to stir for an additional hour [145]. The
mixture was then placed into 3500 molecular weight cut off (MWCO) dialysis bags and
dialyzed in DI water for a minimum of 24 hours. After the initial dialysis, the CS
aldehyde was placed into a acetate buffer bath (pH 4.0, Fisher) for 3 hours before
returning the CS aldehyde to dialysis in DI water for an additional 24 hours [146]. After
dialysis, oxidized chondroitin sulfate was lyophilized for one week and stored in the
fridge prior to use.
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Figure 10: The reaction of CS with sodium periodate for form the bioadhesive CS
aldehyde [15]

3.1.3 – Degree of CS aldehyde Substitution Determination
The degree of substitution (percentage of potential hydroxyl side groups
converted to aldehyde groups) was measured through hydroxylamine hydrochloride
titration using a procedure and calculations adapted from Zhao et al [147]. A solution of
hydroxylamine hydrochloride (HH) was prepared by dissolving 17.5 g of HH in 130 mL
of DI water. Additionally, 6 mL of methyl orange indicator was added and the solution
was brought to a volume of 1L.
For each titration, 25 mL of HH solution was adjusted to a pH of 4 using 0.1N
sodium hydroxide (Fisher) and 100 mg of CS aldehyde was subsequently dissolved into
the HH solution. The mixture was titrated with 0.1N sodium hydroxide, recording
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volume added and pH at 0.05 mL increments until the pH of the solution reached
approximately 4.4.
The calculations to determine the degree of substitution for the CS aldehyde can
be seen below as Equation 2-4. The change in pH was determined for each change in
volume of sodium hydroxide added. The calculation of aldehyde substitution requires
knowledge of the peak pH change per change in volume of titrant added (the derivative
of the pH versus volume added plot) and can be seen graphically as Figure 11. In
Equation 2, the total number of available hydroxyl groups was determined from the
molecular weights of both the CS polymer and CS repeat unit. Subsequently in Equation
3 the number of aldehyde groups created through the oxidation reaction was calculated
and this number was used in Equation 4 to calculate the percentage of aldehyde groups
created through the oxidation of CS. It is important to note that in Equation 4 the
numerator is divided by two because of the two hydroxyl groups present on each CS
repeat unit.
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Figure 11: A graphical representation of the peak pH change per volume added to
determine the cumulative volume of sodium hydroxide added

Equation 2: Calculation of the number of repeat units on each of the CS polymer
chains (the MW of CS was 75,000, obtained from Sigma-Aldrich in August 2011)
Number'of'Repeat'Units'='

MW#of#CS#Polymer
MW#of#CS#Repeat#Unit

Equation 3: Calculation of moles of aldehyde groups present on the CS backbone
(where V is the cumulative volume of sodium hydroxide added in liters at the largest
pH change)
Mole%of%Aldehyde%Groups (V)$(Molarity$of$NaOH)
=
Mole%of%CS%aldehyde
Mole%of%CS%Titrated
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Equation 4: Calculation of the degree of substitution based on the number of
available hydroxyl groups converted to aldehyde groups
!"#$!!"!!"#$ℎ!"#!!"#$%&
%Conversion*to*Aldehyde =

!"#$!!"!!"!!"#$ℎ!"#

Number'of'Repeat'Units

2

3.1.4 – LCST Determination
The LCST was measured using the TA instruments Q2000 Differential Scanning
Calorimeter (DSC). For each test between 5-15 mg of 5% (w/v) PNIPAAm-g-CS was
placed into hermetically sealed aluminum dishes (pre-weighed) and the temperature was
increased from 0-50°C at a rate of 10°C/min. LCST was determined by the endothermic
peak on the DSC thermogram and the LCST was taken as the minimum of this peak.
3.1.5 – Rheological Characterization
Polymer viscosity was tested for each batch to ensure continuity in adhesion
testing procedures. For each batch of 1000:1 PNP-CS polymer synthesized, 80 mL of a
5% solution was made by dissolving 4 grams of PNP-CS in 80 mL of PBS. Viscosity was
tested using a using a Brookfield DV-11+ Viscometer with a #3 spindle and speed
between 20-100 RPM. Average viscosity values were reported by averaging the viscosity
measurements from 20-100 RPM and used to characterize each batch of PNIPAAm-gCS.
3.1.6 – Mechanical Property Characterization
The mechanical properties of the adhesive were tested in tension based on the
ASTM procedure 2258 for tissue adhesives in tension [148]. For testing and data
collection, a Shimpo FGV-0.5X force gauge and Shimpo FGS-200PV E-Force Test Stand
were used. Porcine ear cartilage, obtained from a local butcher, was cut into 1 cm2
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squares. One piece of cartilage was affixed a lower stainless steel weight and one piece of
cartilage to the upper Teflon force gauge attachment. A sample of 0.1 mL was placed on
the lower cartilage using a positive displacement pipette and the system was lowered
applying 0.01 N of preload. Once preloaded, a solution of 0.9% sodium chloride heated
to 37°C was added to completely cover the sample and mimic physiological conditions.
The sodium chloride solution was maintained at 37°C throughout the entire test using a
heating plate. The sample was allowed to form a hydrogel for five minutes prior to
testing.
To test the material, force data was collected using the Shimpo E-Stand software.
The material was separated at a rate of 2 mm/min until the adhesive had been separated
or the test reached 7mm. A representative adhesion test can be seen in Figure 12. Stresses
were calculated by subtracting the force exerted by the polymer from the buoyant force of
a “blank” (Teflon attachment with cartilage alone raised at the same rate) and dividing by
the cross sectional area of cartilage, as seen in Equation 5. The maximum stress was
simply the highest stress obtained during the experiment, graphically the peak of the
stress versus distance curve, seen below in Figure 13.
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Figure 12: A representative adhesion test with adhesive between porcine cartilages

Equation 5: Calculation of stress by subtracting polymer force from the "blank"
buoyant force and dividing by adhesive area
!"#$%% =

!"#$%!!"!!"#$%&' − !"#$%&'!!"#$%!
!"#$!!"!!"#$%&"'(

46

Figure 13: The graph of a representative adhesion test showing the maximum stress

3.1.7 – Liposome Synthesis and Release Studies
Liposomes have been widely used in experimentation as possible drug delivery
vehicles. In this experimentation, liposomes were synthesized using well established
“thin-film” methods [149] [150]. The lipids 1,2-dimyristoyl-sn-glycero-3-phosphocholine
(DMPC) (Avanti Polar Lipids) (6.777 mg) and 1,2-dipalmitoyl-glycero-3-phosphocholine
(DPPC) (Avanti Polar Lipids) (66.06 mg) were dissolved in 3.28 mL of chloroform and
allowed to evaporate under vacuum overnight. The molar ratio of 90% DPPC and 10%
DMPC was used to ensure the liposomes had a melting temperature of 37°C [151]. Dried
lipids films were hydrated in a solution of gelatin in PBS at a concentration of 4 mg
gelatin per mL and allowed to hydrate overnight at 60°C with vortexing periodically.
Liposomes were then extruded with 11 passes through a 0.2 micron filter to break up
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multilamellar vesicles. Once extruded, liposomes underwent dialysis at 4°C in 50,000
MWCO dialysis bags (Spectra/Por) for one week to remove un-entrapped gelatin.
Finished liposomes were stored at 4°C prior to use.
Release studies were performed to quantify the amount of gelatin released.
Loaded liposomes (1.5 mL) were placed into 50,000 MWCO dialysis bags and sealed in a
glass jar containing 100 mL of DI water. The jar was stored at 37°C for 7 days and
samples were taken from the water surrounding the dialysis bag. A standard solution of
0.02 mg/mL of gelatin was prepared in PBS and diluted according to Table 3.

Table 3: Preparation of known concentration solutions for the BCA assay
Gelatin Solution (mL) DI Water (mL) Concentration (mg/mL)
1
6
0
0.02
2
5
1
0.01667
3
4
2
0.01333
4
3.5
2.5
0.01167
5
3
3
0.01
6
2.5
3.5
0.00833
7
2
4
0.00667
8
1.5
4.5
0.005
9
1
5
0.00333
10
0.5
5.5
0.00167
11
0
6
0

A bicinchoninic acid (BCA) assay (Micro BCA™ Protein Assay Kit – Pierce,
Thermo Scientific) was used to quantify the amount of gelatin released from the loaded
liposomes. The BCA working reagent was prepared according to the manufacturer
instructions. The plate allowed to react for approximately two hours at 37°C before being
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read at 562 nm using a Bio-Tek ELx800 plate reader. The standard curve was plotted in
Excel and used as the correlation for determining the concentration released from the
liposome samples.
3.2 – Biological Assays for Cell Viability
3.2.1 – Preparing Cells and Seeding Polymer Mixtures
To test the viability of cells within the polymer matrix, human embryonic kidney
(HEK) 293 cells were utilized. Cell media was prepared by combining 90 mL Dulbecco’s
Modified Eagle Medium (Gibco) containing 4 mM L-Glutamine, 25 mM D-Glucose and
0.0399 mM Phenol Red with 5 mL Fetal Bovine Serum (FBS) (Gibco), 5 mL Calf Serum
(Gibco) and 100 µL penicillin/streptomycin (Pen/Strep). HEK 293 cells were grown at
37°C until 85% confluent. Plates showing 85% confluence were subjected to treatment
with 1 mL of trypsin and incubated at 37°C for 10 minutes to detach cells from the dish.
After trypsinization, 5 mL of warm cell media was added to each plate and plates were
combined into conical tube and lightly mixed to disperse cells.
Cell counts were performed with a hemocytometer counting in the specified
pattern as stated in the instructions. Approximately 10 µL of cell mixture was loaded into
the hemocytometer for counting. Two cell counts were performed for a given cell mix
and averaged for calculations to obtain the average cell count CA. To obtain a
concentration of 106 cells per mL of polymer, Equation 6 and Equation 7 were used.
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Equation 6: Using the average cell count from the hemocytometer, the initial
concentration of cells within the mix was determined
(!! ) 6 5 10! = !! =

!"##$
!"

Equation 7: Calculation of the amount of cell mix needed to seed the polymer with
106 cells per mL (y is the volume of polymer being seeded, x is the volume of cell
mixture required)
1!!"!!!
!!!!!!! !
=
!!
!! − !
10! − 1
3.3

The appropriate volume of cell mixture (x above) was combined with the proper
volume of cell media (y-x above) and centrifuged at 1500 RPM at 4°C for 5 minutes to
pellet cells. Once pelleted, the supernatant was removed and replaced with the proper
amount of polymer mixture (y above). To ensure the cells were evenly distributed within
the polymer, pipetting up and down approximately 20 times dispersed the pellet. Cell
only controls were not subjected to centrifugation, simply diluted with the appropriate
amount of cell media. For each of the assays, 300 µL of each polymer mix was added to
the appropriate wells on a 24 well plate in triplicate. Polymer was allowed to aggregate at
37°C for 10 minutes prior to starting each assay and extruded water was removed. Cells
were covered with cell media and incubated at 37°C for the desired time period prior to
each assay. Prior to each assay, plates were removed from incubation and left at room
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temperature for 24 hours to more easily separate seeded cells from the polymer
formulations.
3.2.2 – PicoGreen Assay
The PicoGreen Assay (Invitrogen) was performed to quantitatively determine the
amount of viable cells within the polymer by staining and counting the number of
nucleotides present in each polymer and control solution mixture. To prepare the
PicoGreen assay, a buffer solution of 1X TE (10 mM Tris-HCl, 1 mM EDTA, pH 7.5)
was prepared by combining 5 mL of 10X TE solution and 45 mL of DNAse free water.
Additionally, a “high range” solution of 2 µg/mL DNA was prepared by mixing 24 µl of
the 0.5 µg/µL lamda DNA with 5.976 mL of TE buffer. This solution was diluted 40-fold
to form the “low range” (50 ng/mL DNA) solution by mixing 150 µl of the 2 µg/mL
DNA in 5.85 mL of TE buffer. Finally, the Quant-iT™ PicoGreen® reagent was
prepared in the dark by first making a 200-fold dilution of DMSO in TE and combining
this with a 150 µl Quant-iT™ PicoGreen® dsDNA reagent in 29.85 mL TE buffer. High
and low range standard curves were prepared by combining TE Buffer, High or Low
range DNA solutions and PicoGreen reagent according to Table 4 and Table 5.
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Table 4: High range standard curve for the PicoGreen assay
Volume (µL) of
Volume (µL)
Volume (µL)
Diluted Quant-iT™
of TE
of 2 µg/mL DNA Stock
PicoGreen® Reagent
0
900
990
999
1,000

1,000
100
10
1
0

1,000
1,000
1,000
1,000
1,000

Final DNA
Concentration
in Quant-iT™
PicoGreen® Assay
1 µg/mL
100 ng/mL
10 ng/mL
1 ng/mL
Blank

Table 5: Low range standard curve for the PicoGreen assay
Volume (µL) of
Volume (µL) of
Volume (µL)
50 ng/mL DNA Diluted Quant-iT™
of TE
Stock
PicoGreen® Reagent
0
900
990
999
1,000

1,000
100
10
1
0

1,000
1,000
1,000
1,000
1,000

Final DNA
Concentration
in Quant-iT™
PicoGreen® Assay
25 ng/mL
2.5 ng/mL
250 pg/mL
25 pg/mL
Blank

Polymer plates were incubated at 37°C for five days then allowed to gel at room
temperature for 24 hours. Cells were first lysed with and DNA was extracted using the
DNeasy Blood and Tissue kit (Qiagen) and following the manufacturer instructions.
Approximately 1 mL of the PicoGreen reagent (150µL of PicoGreen in 29.85 mL of TE
buffer) was added to each well of the 24 well plate and allowed to incubate at room
temperature for 2-5 minutes protected from light. After incubation, 300 µL from each
well was added to the well of a black 96-well plate and read in a spectrofluorometer or
fluorescence at wavelengths of 480 nm for excitation and 520 nm for emission.
Fluorescence values from a reagent blank were subtracted from each of the samples and
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the corrected fluorescent readings for each of the standard curves was plotted to create a
DNA concentration versus fluorescence correlation. This correlation was used to
calculate the DNA concentration in each of the sample wells.
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Chapter 4
Results and Discussion
Aim 1: Synthesize an adhesive copolymer consisting of poly (N-isopropylacrylamide)
graft chondroitin sulfate blended with aldehyde modified chondroitin sulfate and
characterize the material properties
The graft copolymer was synthesized in a molar ratio of 1000:1 (NIPAAm:mCS)
and the lower critical solution behavior was verified through differential scanning
calorimetry (DSC). The lower critical solution temperature of the copolymer was found
to be between 30.5-31.5°C, slightly higher than the LCST of the homopolyer at 29.6°C,
however still in the range to for a hydrogel in situ. The increase in LCST was also seen
by other researchers and can be attributed to an increase in water content of the
copolymer, requiring more energy to break the additional hydrogen bonds formed with
the PNIPAAm below the LCST [152] [153]. Additionally, rheology was used as an
indicator of molecular weight range. It was determined that using consistent viscosity
will yield consistent adhesion testing results. The rheological characteristics of solutions
containing 5% (w/v) PNIPAAm-g-CS were examined and found to have optimal
adhesive characteristics when the average viscosity ranged from 800-1000 cP.
Chondroitin sulfate aldehyde (CS aldehyde) was synthesized using various mass
ratios of sodium periodate to chondroitin sulfate. Mass ratios of 0.5:1, 1:1 and 2:1 of
sodium periodate:CS were used to generate varying degrees of substitution, converting a
different number of hydroxyl groups present on the CS backbone to aldehyde groups. The
aldehyde degree of substitution was tested using the hydroxylamine hydrochloride
titration method adapted from Zhao et al [147]. These different ratios yielded degrees of
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substitution seen below in Table 6. Each of the mass ratios used produced a statistically
different (p<0.05) degree of substitution on the CS aldehyde.

Table 6: The effect of varying the mass ratio of sodium periodate to CS on degree of
substitution
Mass Ratio Sodium Periodate : CS
Average Degree of Substitution (%)

0.5:1
33.86

1:1
42.39

2:1
72.17

95% Confidence Interval (%)

1.24

3.06

14.45

Tensile testing using a solution of 5% (w/v) PNIPAAm-g-CS hydrated in
phosphate buffered saline (PBS) combined with 3% (w/v) CS aldehyde using the three
degrees of substitution was carried out. As seen in Figure 14, varying the degree of
substitution of CS aldehyde produces no statistically significant (p>0.05) differences in
the adhesive strength of the copolymer. However, using the 5% PNIPAAm-g-CS solution
as a control, it can be seen that the incorporation of any degree of substitution CS
aldehyde produces a statistically significant (p<0.05) increase in adhesive strength over
samples containing no CS aldehyde. It is theorized that while more aldehyde groups may
be present with increased CS aldehyde degree of substitution, the reaction is limited by
how many of these aldehyde groups can reach the surface, therefore causing no increase
in adhesion with more aldehyde groups present.
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Figure 14: The effects of varying degree of substitution on maximum stress (error
bars represent 95% confidence intervals)

Although the results show limited variability in the adhesive strength of the
scaffold, it is important to recall the biocompatibility of the system can be affected by the
presence of excess aldehyde groups as shown in literature [20] [21]. Therefore there is no
benefit to increasing the degree of substitution of CS aldehyde. Optimization of the
system should, therefore, only focus on minimizing the cytotoxic effects of CS aldehyde
on surrounding cells and tissues. For this reason, it is important to choose a lower degree
of substitution that has minimal effects on cell life. In subsequent testing, a degree of
substitution of 42% CS aldehyde was used.
Next, the effects of varying the concentration of CS aldehyde within the polymer
matrix were investigated. The degree of substitution for these tests was held constant at
42% while the concentrations of CS aldehyde concentrations in copolymer solution at
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room temperature were varied from 0, 1, 3 and 5% (w/v). Tensile tests results for varied
weight percentage of CS aldehyde can be seen in Figure 15.
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Figure 15: The effects of varying weight percentage of CS aldehyde in copolymer
solution at room temperature on maximum stress (error bars represent 95%
confidence intervals)

In these tests, 3% CS aldehyde was shown to have a statistically (p<0.05) higher
maximum stress. The concentration of CS aldehyde within shows an increase in adhesive
strength from no CS aldehyde to 3% CS aldehyde where there is a maximum. This
indicates that increasing CS aldehyde concentration initially increases the adhesive
strength. Above 3% CS aldehyde, the adhesive strength begins to decrease. Formulations
of 5% CS aldehyde showed an increase in viscosity that can be attributed to the decrease
in adhesive strength beyond 3% CS aldehyde. To achieve maximum adhesion,
mechanical interlocking must take place between the uneven surface of the tissue and the
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CS aldehyde adhesive filling these voids and forming the covalent bonds via the Schiff’s
base reaction. With an increased viscosity sample, it is more difficult for the polymer to
fill these voids on the tissue surface and therefore the adhesive strength of the sample
decreases as the viscosity of the sample increases.
In summary, in Aim 1 it was determined that the copolymer had a LCST of
between 30.5-31.5°C, an increase over the homopolymer which had an LCST of
approximately 29.6°C. Additionally, the copolymer performed optimally in adhesive
testing when the viscosity ranged from 800-1000 cP. There were found to be no increases
in the adhesive strength of the polymer when the degree of substitution was increase,
likely limited by the number of available reaction sites on the cartilage and aldehyde
groups able to reach these reaction sites. Finally, varying weight percentage showed that
the highest adhesive strength was achieved using a solution containing 3% (w/v) CS
aldehyde, above this critical concentration, the viscosity increases too drastically and
adhesive strength decreases.
Aim 2: Prepare lipid vesicles hydrated with ECM derivatives, verify ECM derivative
release, and combine lipid vesicles with the scaffold prepared in Aim 1 and characterize
the adhesive properties of the system.
To combat the cytotoxic effects of aldehyde groups, ECM loaded lipid vesicles
(liposomes) were used as a controlled release mechanism, assuming that excess aldehyde
groups would react with the ECM derivative upon liposome melting at body temperature.
Theoretically, heating of the polymer allows the Schiff’s base reaction with the tissue to
take place, ensuring maximum adhesion, prior to the release of gelatin from the
liposomes. However, liposome melting should be fast enough to prevent cytotoxic events
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from occurring after adhesion with the CS aldehyde and tissue has occurred. Gelatin was
chosen as the ECM derivative because of its low cost. Lipid vesicles (22.2 mg dry lipids
per mL of solution) hydrated in a solution of 4 mg/mL of gelatin in PBS were shown to
release approximately 0.622 mg gelatin/mL of solution, verified with a BCA assay after
seven days of release at 37°C. Negligible amounts of gelatin were released at 4°C.
Tensile testing was used to determine the effects of liposome concentration on
adhesion. Samples containing 5% (w/v) PNIPAAm-g-CS and 3% (w/v) CS aldehyde
were used. Liposomes hydrated with 4 mg/mL of gelatin were diluted to obtain solutions
with 0, 2.78, 5.55, 11.1 and 22.2 mg dry lipids per mL of liposome solution. The results
of tensile testing results can be in Figure 16.
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Figure 16: The effects of varying liposome concentration in room temperature
copolymer solution on maximum stress (error bars represent 95% confidence
intervals)
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It can be seen that increasing the liposome concentration causes a significant
decrease in the adhesive strength of the copolymer solution, however this could be
attributed to either the lipid or gelatin component of the liposomes. It was theorized that
the lipid component was preventing mechanical interlocking, and therefore effect
adhesion from taking place and this was investigated further.
In order to determine the effect of each component, tensile tests were performed
using samples containing no lipids (free gelatin) and samples with no gelatin (unloaded
liposomes) in comparison with the adhesive properties of systems with copolymer only,
copolymer and adhesive and copolymer adhesive and liposome samples. All solutions
contained 5% (w/v) PNIPAAm-g-CS and solutions with adhesive contained 3% (w/v) CS
aldehyde. The CS aldehyde degree of substitution was again held constant at 42%.
Tensile test results for adhesive strength can be seen in Figure 17.
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Figure 17: The effects of lipids, gelatin and liposomes on maximum stress (error
bars represent 95% confidence intervals)

The addition of free gelatin at a concentration comparable to what was measured
in the liposome release studies slightly reduced adhesive strength to a level that was
statistically similar to that seen with PNIPAAm-g-CS alone, indicating the need for
encapsulation of gelatin. The addition of both lipids, loaded or unloaded, significantly
(p<0.05) decreased maximum stress. The decrease in adhesive strength from liposome
addition (loaded and unloaded) to the matrix is thought to have occurred by interacting
the interface of adhesive and tissue. As was previously mentioned, the adhesive
component of the system relies on mechanical interlocking to take place in order to form
effective covalent bonds with the tissues. The liposomes, being composed of fatty acids,
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are thought form a “slippery layer” which prohibits the CS aldehyde from effectively
contacting the tissue surface and therefore covalent and hydrogen bonds cannot form.
Incorporation of increasing amounts of CS aldehyde causes an increase in the
adhesive strength of the polymer matrix, while incorporation of increasing lipid content
causes a decrease in adhesive strength, a result expected from the study with free gelatin,
loaded and unloaded liposomes.
Aim 3: Demonstrate the ability of the tissue engineering scaffold to support encapsulated
cell survival
The biocompatibility of the polymer system was examined using the solution that
presented the highest adhesive properties (5% PNIPAAm-g-CS with 3% CS aldehyde)
and the solution that would release the maximum amount of gelatin (5% PNIPAAm-g-CS
with 3% CS aldehyde and 22.2 mg dry lipids/mL). It was hypothesized that solutions
with no liposomes should show signs of cytotoxicity from aldehyde groups present on the
CS aldehyde adhesive, while solutions containing liposomes would show a recovery in
the biocompatibility of the system. Human embryonic kidney (HEK) 293 cells were used
to examine the biocompatibility and were seeded within the aforementioned adhesive
scaffolds at a density of 106 cells per mL for 5 days at 37°C. Additionally, the
biocompatibility of the polymer alone was examined. As a control, a monolayer of cells
without polymer was used. A PicoGreen assay was used to examine the biocompatibility
and results can be seen in Figure 18.
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Figure 18: Biocompatibility of polymer formulations with and without liposomes,
compared with polymer only and cell only control samples. Cells were seeded at 106
cells per mL and incubated for 5 days at 37°C (error bars represent standard
deviation)

The biocompatibility of the system performed as expected. The addition of CS
aldehyde into the system causes a decrease in the biocompatibility, likely due to the
presence of excess aldehyde groups. Addition of liposomes allows for the release of
gelatin and an increase in the overall biocompatibility of the system. Additionally, it
appears that the liposomes were able to release gelatin quickly enough to prevent
cytotoxic events from occurring, a criteria for their use in the adhesive scaffold. While
these results seem to indicate a biocompatible system, additional preliminary
biocompatibility testing (data and procedures shown in Appendix A) seems to indicate
that liposomes may contribute to the cytotoxicity of the system.
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Overall, there are conflicting choices when optimizing both the biocompatibility
and maximum adhesion of the system. These data demonstrate that the optimum adhesive
system is one containing no lipid component, as the lipids negatively affect the adhesive
strength. Conversely, the optimal biocompatible system is one that contains some way of
incorporating an ECM derivative to interact with the excess aldehyde groups present
from the adhesive CS aldehyde. As an alternative of achieving the release of gelatin into
the system, gelatin loaded alginate microparticles could be examined. Alginate makes an
appealing choice because, as a polysaccharide like CS, alginate could theoretically
hydrogen bond with the tissue surface, theoretically having adhesive characteristics of the
graft copolymer alone. In this system, alginate would be crosslinked and physically
entrap the gelatin within, allowing for the release based on diffusion principles.
Additionally, alternative methods for increasing the adhesion could be examined,
including adhesives that may present more favorable biocompatibility characteristics
while increasing the overall adhesive strength of the system. In addition, to optimize the
system a number of other characteristics can be examined. These include looking at the
degradation of the system, MSC differentiation in vitro, and the compressive mechanical
characteristics over time. In future work, these avenues should be examined as a means of
creating a tissue engineered scaffold with optimal characteristics for both adhesion and
cell survival in vitro.
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Chapter 5
Conclusions and Recommendations
In this work a novel, in situ forming, adhesive hydrogel scaffold was synthesized
and characterized. A copolymer scaffold of PNIPAAm-g-CS was synthesized and the
LCST was found to be between 30.5-31.5°C, a slight increase over the homopolymer
with a LCST of 29.6°C. In addition, CS aldehyde was also successfully synthesized and
the degree of substitution was verified through hydroxylamine hydrochloride titration.
The adhesive CS aldehyde was successfully synthesized with three degrees of
substitution by varying the mass ratio of sodium periodate, the oxidizing agent, in the
reaction. These degrees of substitution are specifically, 33, 42 and 72%.
The mechanical properties of the copolymer and adhesive were examined. First,
the degree of substitution of CS aldehyde was tested with a copolymer only control. The
degree of substitution was found to have no impact on the adhesive strength of the
scaffold, however incorporation of CS aldehyde produced significantly higher (p<0.05)
adhesive strength than the copolymer alone. From this, it was concluded that for
maximum biocompatibility, the system with fewer aldehyde groups should be used for
subsequent testing. For this reason, all subsequent testing used a CS aldehyde degree of
substitution of 42%. Additionally, the weight percentage of CS aldehyde within the
copolymer scaffold was varied. The adhesive properties of adhesive scaffold containing
0, 1, 3 and 5% (w/v) CS aldehyde were tested. Initially, incorporation of more CS
aldehyde increased the adhesive strength, up to the optimum of 3% (w/v) CS aldehyde.
This was an expected result, as more aldehyde groups present should form more bonds
with the tissue surface. When the weight percentage of CS aldehyde was increased to 5%
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(w/v), there was a marked increase in the viscosity of the sample, observed during
experimentation. It is theorized that this viscosity increased prevented samples of 5%
(w/v) CS aldehyde from mechanically interlocking with the tissue and therefore causing a
decrease in the adhesive properties of the system at this concentration.
In an effort to increase the biocompatibility of the system, ECM loaded lipid
vesicles were synthesized. Liposomes were formulated to melt at body temperature and
hydrated in solutions of 4 mg/mL gelatin in PBS. These liposomes were shown to release
approximately 0.622 mg gelatin/mg dry lipids over a 7 day period at 37°C. Additionally,
the mechanical properties of the adhesive system were examined with lipid vesicles
incorporated throughout. The concentration of lipids was varied in a system containing
5% (w/v) PNIPAAm-g-CS in PBS and 3% (w/v) CS aldehyde. This system showed as
lipid concentration increased, there was a decreasing trend in the adhesive strength of the
system. In an effort to determine if this was the effect of the gelatin released from the
liposomes or the lipids themselves, the mechanical properties of each component of the
liposomes was examined. When un-encapsulated gelatin (“free gelatin”) was included in
the system, the adhesive strength was statistically similar to the grafter copolymer alone,
indicating the need for encapsulation. Additionally, including both loaded and unloaded
lipid vesicles caused a significant decrease (p<0.05) in adhesive strength over both
copolymer alone and copolymer with CS aldehyde. This decrease in adhesive strength
could be attributed to the lipid component of the liposomes. This is theorized to be a
result of lipids preventing mechanical interlocking from taking place at the tissue surface
by forming a “slippery layer” at the interface of the scaffold and tissue.
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Finally, the preliminary biocompatibility of the adhesive scaffold was examined
by encapsulating HEK 293 cells. Formulations containing 5% (w/v) PNIPAAm-g-CS,
5% (w/v) PNIPAAm-g-CS with 3% (w/v) CS aldehyde and 5% (w/v) PNIPAAm-g-CS
with 3% (w/v) CS aldehyde and 22.2 mg/mL liposomes were seeded with HEK 293 cells
at a density of 106 cells/mL and incubated at 37 for 5 days. These preliminary results
demonstrate that the grafted copolymer alone is relatively biocompatible when compared
to the cell only control. Addition of CS aldehyde adhesive into the system causes a
decrease in the biocompatibility, likely due to the presence of excess aldehyde groups,
while incorporation of liposomes causes a recovery in the biocompatibility of the
scaffold, likely due to the release of gelatin in the system. Ultimately, these results
indicate that the thermally triggered release of gelatin from lipid vesicles is sufficient to
cause an increase in biocompatibility.
While it was demonstrated that there is a need for gelatin encapsulation and that
liposomes are capable of encapsulating and releasing gelatin to maintain the
biocompatibility of the system, lipids were shown to significantly (p<0.05) decrease the
adhesive strength of the system. Therefore, future work should investigate the use of
alternative encapsulation methods for the controlled release of gelatin within the adhesive
scaffold. One technology that could be of particular interest is the release of gelatin using
alginate microparticles. These alginate particles could be synthesized simply using a
solution of sodium alginate and calcium as the divalent crosslinking agent. In current
research, this method has been shown capable to encapsulating and releasing growth
factor via simple diffusion [154]. Additionally, because alginate is a polysaccharide
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component, much like CS, it is theorized that adhesive strength should be at least similar
to the grafted copolymer alone.
In addition to examining the encapsulation of gelatin, examining the adhesive
properties of the system further should be considered in future work. Specifically, the
adhesive strength of CS aldehyde should be compared to commercially available
adhesives, such as fibrin. Fibrin should be subjected to the same test protocol as the CS
aldehyde adhesive examined in this work, allowing for comparable data. By comparing
CS aldehyde to fibrin, the determination can be made as to if there is a sufficient increase
in the adhesive strength by incorporating CS aldehyde or if alternative adhesive
chemistry needs to be examined.
Overall, the adhesive system developed shows promise for the repair and
regeneration of damaged IVD tissue. The optimal adhesive properties were shown to
occur with a weight percentage of 3% (w/v) CS aldehyde, and encapsulation of gelatin
with lipid vesicles was shown to increase the biocompatibility of the system over systems
with no lipid vesicles. While alternative encapsulation techniques have the potential to
increase the biocompatibility of the system while maintaining adhesive properties, this
work has made large strides in the development of adhesive scaffolds for IVD repair.
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Appendix A – Supplemental Biocompatibility Procedure and Data
A.1 – Additional Biocompatibility Procedures
A.1.1 – Live/Dead Assay
Live/Dead (LD) assays were performed to obtain a qualitative analysis of the
viability of cells in each polymer mixture. The LD dye mixture was created by mixing
6.67 µL ethidium bromide (EtBr), 2.5 µL of Calcein and 5 mL of PBS in a dark or
covered conical tube and the mixture was vortexed thoroughly. Control wells of PNP-CS
polymer seeded with cells and cell only wells were used. As a negative control, the media
above the PNP-CS polymer seeded with cells was removed and replaced with 200 µL or
70% methanol and the polymer was incubated at 37°C for 30 minutes. The media above
each of the other polymer samples with and without cells and control wells was removed
while the plate was heated from below to prevent phase transition. Wells were washed
with 500 µL of warm PBS prior to the addition of 300 µL of LD dye mixture to each
well.
Once dyed, the plate was incubated for 40-60 minutes at room temperature while
covered on a shaking tray to ensure even distribution of the LD dye. Immediately prior to
microscopy, an additional 10 µL of LD dye was added to each well. Cells were viewed
using a fluorescence microscope with Filtersatz 15 shift adjusted, showing live cells as
bright green and dead cells as red.
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A.2 – Additional Biocompatibility Data
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Figure 1A: Biocompatibility of polymer formulations with and without liposomes,
compared with polymer only and cell only control samples using the PicoGreen
Assay. Cells were seeded at 106 cells per mL and incubated for 5 days at 37°C (error
bars represent standard deviation)
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Figure 2A: Control Live/Dead wells. A cell only live well (green) and cells seeded in
graft copolymer killed with methanol (red)
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Figure 3A: Live/Dead images showing viability of cells within the copolymer alone,
however dead cells in copolymer and CS aldehyde adhesive, and dead cells in
copolymer, CS aldehyde adhesive and liposome blends
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